Is the CSL Limited (ASX: CSL) share price going to go up after partnering with SAB Biotherapeutics?
The Australian Financial Review is reporting that CSL Behring is partnering with the clinical-stage biopharmaceutical development company which is advancing a new class of immunotherapies.
There are multiple agreements that relate to collaboration and options that will explore the possibility and potential of new therapies that will treat challenging autoimmune, infectious and idiopathic diseases by using SAB’s technology platform which naturally and rapidly produces large amounts of antibodies without using human donors.
The initial phase of the plan is expected to be completed in 2020. CSL and SAB will share the costs of the research program and the related expenses, which may lead to further agreements.
CSL is one of the world’s leading companies in biotherapies with a very large budget for research & development each year. It’s agreements like this that help CSL remain at the leading edge of the healthcare industry.
The leadership of both CSL and SAB seem excited by the deal. The AFR quoted CSL senior vice president of research Andrew Nash, “CSL Behring is committed to the continuous development of innovative therapies that address unmet needs for patients with rare and serious diseases. This collaboration will provide both companies an opportunity to explore the potential of these new approaches to positively impact areas of need.”
Eddie J Sullivan, the co-founder and CEO of SAB, said: “We believe combining our unique human antibody development and production capabilities with CSL Behring’s established immunoglobulin franchise and vast expertise in biopharmaceutical development will broaden therapeutic possibilities.”
The CSL share price ended today higher by almost 1% despite the troubles going on in the Middle East. This could be an exciting step for a new wave of products, but we’ll have to see if the partnership amounts to anything special.
The post CSL makes new US-based partnership, will the share price rise? appeared first on Motley Fool Australia.
CSL shares remain highly valued by investors, so it could be a good idea to just focus on good value growth shares like these ones.
Our Motley Fool experts have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.7% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares for 2019
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2019
- 5 Stocks for Potentially Building Wealth After 50
Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2020